[Alpha Tau in PR Newswire] Alpha Tau announces receipt of radioactive license to allow production in main manufacturing floor at its Jerusalem site, amended radioactive license with increased capacity at Lawrence, MA site 

[Alpha Tau in PR Newswire] Alpha Tau announces receipt of radioactive license to allow production in main manufacturing floor at its Jerusalem site, amended radioactive license with increased capacity at Lawrence, MA site 

[ad_1]

JERUSALEM, June 16, 2022 /PRNewswire/ — Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that the Israeli Ministry of Environmental Protection has granted the Company an active radioactive license for use and possession of Thorium-228 and Radium-224, radioactive materials which are utilized in the production of the Alpha DaRT sources, in the main manufacturing floor of the Company’s production facility in Jerusalem.

Read more here.

[ad_2]